This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocel...
- Recurrence
- Endometrial Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Colorectal Neoplasms
- Carcinoma, Hepatocellular
- Adenocarcinoma Of Esophagus
- Carcinoma, Transitional Cell
- Ovarian Neoplasms
- Uterine Cervical Neoplasms
- Biliary Tract Neoplasms
- Melanoma
- Carcinoma, Neuroendocrine
Age: 18 years - 66+
Gender: All